IMMUTEP

Immutep's phase I trial of IMP-761 shows no safety issues; PYC Therapeutics updates on Phelan-McDermid syndrome program; Percheron Therapeutics to release phase 2b Duchenne muscular dystrophy trial results. Control Bionics expects 15%+ sales surge driven by Neuronode device. Botanix Pharmaceuticals ships first US prescriptions for Sofdra anti-sweating treatment.

Immutep (ASX:IMM) initiates TACTI-004 Phase III trial to evaluate eftilagimod alfa (efti) for first-line metastatic NSCLC, in combination with Keytruda and chemotherapy vs. standard treatment. The double-blind study will enroll ~750 patients across 150+ sites in 25+ countries, measuring progression-free and overall survival. CEO Marc Voigt highlights potential for new standard of care, with first patient enrollment expected Q1 2025.

Immutep initiated TACTI-004 Phase III trial for first-line metastatic non-small cell lung cancer treatment, approved by Australia's Therapeutic Goods Administration. The global study will evaluate eftilagimod alfa in combination with KEYTRUDA® and chemotherapy against KEYTRUDA with chemotherapy and placebo, involving 750 patients across 150+ sites in 25+ countries. First patient enrollment expected in Q1 2025.

Aulos Bioscience announced the first patients dosed in a Phase I/II trial investigating avelumab, in combination with imneskibart and low-dose, subcutaneous aldesleukin, for non-small cell lung cancer. The trial follows a collaboration and supply agreement with Merck, evaluating the combination therapy for second-line treatment. Pre-clinical results showed strong anti-cancer activity, including complete tumour eradication.

Immutep announced promising Phase II trial results for eftilagimod alpha combined with pembrolizumab and radiotherapy in treating soft tissue sarcoma, showing significant tumor hyalinization increase.

The phase 1 INSIGHT-003 trial showed that adding eftilagimod alpha (efti) to pembrolizumab and chemotherapy improved overall survival (OS) and progression-free survival (PFS) in first-line metastatic nonsquamous non–small cell lung cancer patients, with a median OS of 32.9 months and a median PFS of 12.7 months, compared to historical controls.

Immutep reports positive FDA feedback on TACTI-004 Phase III trial for first-line non-small cell lung cancer, successful dosing in IMP761 Phase I trial for autoimmune diseases, and inclusion in S&P ASX300 Index. The company maintains a strong cash position with A$172.3 million as of September 2024.